Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

November 10, 2017: By Jon Swedien

alimera-sciencesAlimera Sciences posted Q3-2017 net revenues of $9.8 million, an 18 percent increase compared with Q3-2016, the company reported Nov. 1.

The Alpharetta, Georgia-based company markets Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of diabetic macular edema (DME).

Iluvien is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid with a single injection, Alimera said. It received US approval in September 2014 and is also available in 17 other countries.

Alimera CEO Dan Myers told investors in a conference call Nov. 2 that the company’s sales force was using study data to urge doctors to use Iluvien more frequently.

Typically, doctors have used Iluvien with patients who have not responded well to anti-VEGFs, Myers said. The study data, however, showed that Iluvien could lessen treatment burden for patients whose DME is well controlled by anti-VEGFs, Myers said.

The data he referred to showed that treatment with Iluvien lessened some patients’ need for anti-VEGF injections from once every 2.9 months to once every 22 months, Alimera said.

The study was conducted at four practices, involved more than 20 physicians, and included 130 patients (160 eyes), Myers said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023